Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Zongertinib Yields Clinical Benefit in Previously Treated, HER2-Mutated, Advanced NSCLC

April 28th 2025, 2:48pm

AACR Annual Meeting

Zongertinib provided clinical benefit in previously treated advanced non–small cell lung cancer harboring HER2 mutations.

Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC

April 28th 2025, 12:37am

AACR Annual Meeting

Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.

Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity

April 27th 2025, 11:40pm

AACR Annual Meeting

Olaparib plus pembrolizumab was safe and effective in HRR gene–mutated and/or HRD-positive advanced tumors.

First-Line Penpulimab Plus Chemo Extends PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma

April 27th 2025, 10:45pm

AACR Annual Meeting

Penpulimab plus chemotherapy improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.

TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC

April 27th 2025, 10:30pm

American Urological Association Annual Meeting

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Perioperative Pembrolizumab Poses a New Standard of Care Option in Resectable, Locally Advanced HNSCC

April 27th 2025, 8:27pm

AACR Annual Meeting

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

Zoldonrasib Shows Encouraging Early Antitumor Activity in KRAS G12D–Mutated NSCLC

April 27th 2025, 7:45pm

AACR Annual Meeting

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

Neoadjuvant Mitomycin C Demonstrates Favorable Safety and Potential RFS Benefit in NMIBC

April 27th 2025, 7:31pm

American Urological Association Annual Meeting

Neoadjuvant mitomycin C improved 18-month recurrence-free survival and demonstrated favorable safety in non–muscle-invasive bladder cancer.

Dr Jacob on the Potential for TAR-200 to Shift the Treatment Paradigm in NMIBC

April 27th 2025, 6:26pm

American Urological Association Annual Meeting

Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.

Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC

April 27th 2025, 6:25pm

American Urological Association Annual Meeting

Colin P.N. Dinney, MD, discusses urinary genomic disease burden as a potential biomarker for response to cretostimogene grenadenorepvec in bladder cancer.

Disitamab Vedotin/BCG Could Provide a New Bladder Sparing Therapy in HER2-Expressing High-Risk NMIBC

April 27th 2025, 5:20pm

American Urological Association Annual Meeting

The addition of disitamab vedotin to BCG demonstrated high CR rates in HER2-expressing, high-risk NMIBC.

Nogapendekin Alfa Inbakicept Displays Efficacy in BCG-Unresponsive NMIBC

April 27th 2025, 5:04pm

American Urological Association Annual Meeting

Nogapendekin alfa inbakicept demonstrated sustained CR rates in patients with high-risk BCG-unresponsive NMIBC.

UGN-102 May Represent Alternative to TURBT in Recurrent Low-Grade Intermediate-Risk NMIBC

April 27th 2025, 1:50pm

American Urological Association Annual Meeting

UGN-102 elicits robust responses with acceptable tolerability in recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

Neoadjuvant Niraparib Fails to Produce Substantial Pathologic Responses After Radical Prostatectomy in DDR-Deficient Prostate Cancer

April 26th 2025, 10:55pm

American Urological Association Annual Meeting

No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.

Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab Displays Efficacy in Advanced Urothelial Carcinoma

April 26th 2025, 9:25pm

American Urological Association Annual Meeting

Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.

TAR-200 Produces Unprecedented CR Rates in BCG-Unresponsive, High-Risk NMIBC

April 26th 2025, 9:25pm

American Urological Association Annual Meeting

TAR-200 showed promising results in treating patients with BCG-unresponsive, high-risk NMIBC, achieving an 82.4% complete response rate.

Cretostimogene Grenadenorepvec Produces Durable CRs in High-Risk BCG-Unresponsive NMIBC

April 26th 2025, 9:04pm

American Urological Association Annual Meeting

Cretostimogene grenadenorepvec generated complete responses in patients with high-risk BCG-unresponsive NMIBC and CIS with or without Ta/T1 tumors.

TAR-200 Yields Prolonged DFS in BCG-Unresponsive, Papillary High-Risk NMIBC

April 26th 2025, 9:03pm

American Urological Association Annual Meeting

TAR-200 produced durable disease-free survival in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC

April 26th 2025, 8:13pm

American Urological Association Annual Meeting

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.

MRD Assessment Informs RFS Outcomes With Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC

April 26th 2025, 5:02pm

American Urological Association Annual Meeting

Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.